about
CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro dataCharacterization of respiratory drug delivery with enhanced condensational growth using an individual path model of the entire tracheobronchial airwaysEvaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulationTargeted Lung Delivery of Nasally Administered AerosolsImproving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG)Targeting aerosol deposition to and within the lung airways using excipient enhanced growthVariability in Nose-to-Lung Aerosol DeliveryCharacterization of Nanoaerosol Size Change During Enhanced Condensational GrowthEvaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial modelValidating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo DataChromatographic and mass spectral characterization of budesonide and a series of structurally related corticosteroids using LC-MS.Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases.Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor XaDevelopment of high efficiency ventilation bag actuated dry powder inhalers.Dynamic affinity chromatography in the separation of sulfated lignins binding to thrombin.Optimal delivery of aerosols to infants during mechanical ventilation.Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle AerosolsCondensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental resultsProduction of Highly Charged Pharmaceutical Aerosols Using a New Aerosol Induction Charger.Generating Charged Pharmaceutical Aerosols Intended to Improve Targeted Drug Delivery in Ventilated InfantsEfficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds.Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung.Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components.The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy.Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols.Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics.Control of particle size by coagulation of novel condensation aerosols in reservoir chambers.Structural characterization of a serendipitously discovered bioactive macromolecule, lignin sulfate.Effect of energy on propylene glycol aerosols using the capillary aerosol generator.Stability and characterization of perphenazine aerosols generated using the capillary aerosol generator.Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths.Intermittent aerosol delivery to the lungs during high-flow nasal cannula therapy.Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties.
P50
Q28383212-FE8CEB1C-C986-4D3D-8DE9-C8260FC6F180Q28386376-1FBC0882-02B4-4124-AB0A-476F7FF64CDFQ28387314-8DD98122-2107-4312-B765-B121C9A952E9Q28387568-CC0B3168-FEF0-432D-8C66-34866DFEC971Q28389833-8633E02B-E572-4827-962C-D39871EC9612Q28390979-F1F4B3DD-B00F-4C12-AA15-BA42EAA602D2Q28395392-09132BFE-444A-422F-BB73-763799AC4FC7Q28396996-11DCCD77-6F19-49F0-8F41-96ACE95542D8Q28397573-D3E9B4ED-386A-4685-BD43-0E9AF48F0473Q30945192-781A537A-203C-4E9E-9248-D78688077C56Q33216104-F27D13CD-1E5F-4600-A0F5-B97C53480743Q33254268-634CB003-A9D6-4DB1-A53A-E42E20F62539Q33379903-E53C95D8-92F1-4193-8099-93576FB8D78DQ33470885-85316D2F-E44F-449D-BD5F-5C86592D2776Q33732483-CA66C7BB-9327-4749-AD59-AB86C89D14E9Q33905734-3131E01E-C6F3-4ADE-AB34-7415CA6EB192Q34488035-030E2C6B-76AE-4EA5-944D-156BBB459AC2Q35127772-6EDE35CD-4112-4313-81C5-ED15BAD5213DQ35784530-8BF85025-71A3-46F7-9EF1-E34B4CB0CA43Q35929010-3D17D3C6-D9AE-4DFF-B214-33136C730A28Q35934835-54B4CC50-06D6-4134-AFAE-7C5850E16998Q36024362-6E4060DD-1D19-48A2-998A-AD9A9A2A4D1CQ36156550-D7C6B127-2EE2-4F17-9D0E-3E71907D9CB6Q36200226-F72B465C-2E76-414C-A4B7-61B0EAD2D12FQ36282208-80ABBD77-E1D3-434B-80EA-12913FA7B29BQ36568020-82EC0966-AF22-44CA-A358-65E751364656Q36824193-022960EE-73FD-4423-B78C-E5850175C204Q37238872-FD433317-0CBA-4285-8D24-FCDAA0B43258Q37625308-01DE9E94-EC70-4723-BCC7-E3FDDF2FC007Q37626575-E2A68ED0-6D7B-49BC-9A4C-7034B25C91F4Q37816438-95154E1F-B75F-4056-9486-BE97FD046F35Q39848034-716C0D14-FE3C-4614-8A98-ECD3D5D280D2Q42572439-61CCF54F-D969-4A69-8729-303CA0AE5FE3Q44311872-3B18902B-8A35-4BC3-8357-38672DE2B876Q44807016-25DD3948-8EA0-4479-BA28-3207EECFEC89Q44841900-ED40D7DA-5973-41BE-BDD6-D17E066D061DQ44913353-5F9350D2-C66D-471D-8569-F6043966BB7EQ44947827-7BB64633-976E-400E-9792-4AC1C19F7F5DQ44999160-5A95E8AE-5F27-4D4C-B6BE-6B5C55CF26FDQ45023809-5BD5F822-A4EB-4651-99A4-D31AF61B047D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Hindle
@ast
Michael Hindle
@en
Michael Hindle
@es
Michael Hindle
@nl
Michael Hindle
@sl
type
label
Michael Hindle
@ast
Michael Hindle
@en
Michael Hindle
@es
Michael Hindle
@nl
Michael Hindle
@sl
prefLabel
Michael Hindle
@ast
Michael Hindle
@en
Michael Hindle
@es
Michael Hindle
@nl
Michael Hindle
@sl
P108
P106
P1153
6701647731
P31
P496
0000-0002-1025-1183